These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 23273339)

  • 1. Exploring the reduction in myocardial infarctions in the PLATO trial: which patients benefited on ticagrelor vs. clopidogrel?
    DiNicolantonio JJ; Serebruany VL
    Int J Cardiol; 2013 May; 165(3):396-7. PubMed ID: 23273339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating the risk-benefit profile of the direct-acting P2Y(12) inhibitor ticagrelor in acute coronary syndromes.
    Husted S
    Postgrad Med; 2011 Nov; 123(6):79-90. PubMed ID: 22104457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduction in first and recurrent cardiovascular events with ticagrelor compared with clopidogrel in the PLATO Study.
    Kohli P; Wallentin L; Reyes E; Horrow J; Husted S; Angiolillo DJ; Ardissino D; Maurer G; Morais J; Nicolau JC; Oto A; Storey RF; James SK; Cannon CP
    Circulation; 2013 Feb; 127(6):673-80. PubMed ID: 23277305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lessons from platelet inhibition and patient outcomes.
    Held C
    Curr Opin Cardiol; 2012 Jul; 27(4):355-60. PubMed ID: 22565140
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiographic outcomes in the PLATO Trial (Platelet Inhibition and Patient Outcomes).
    Kunadian V; James SK; Wojdyla DM; Zorkun C; Wu J; Storey RF; Steg PG; Katus H; Emanuelsson H; Horrow J; Maya J; Wallentin L; Harrington RA; Gibson CM
    JACC Cardiovasc Interv; 2013 Jul; 6(7):671-83. PubMed ID: 23866179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of ticagrelor and clopidogrel in primary percutaneous coronary intervention.
    Velders MA; Abtan J; Angiolillo DJ; Ardissino D; Harrington RA; Hellkamp A; Himmelmann A; Husted S; Katus HA; Meier B; Schulte PJ; Storey RF; Wallentin L; Gabriel Steg P; James SK;
    Heart; 2016 Apr; 102(8):617-25. PubMed ID: 26848185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial.
    Held C; Asenblad N; Bassand JP; Becker RC; Cannon CP; Claeys MJ; Harrington RA; Horrow J; Husted S; James SK; Mahaffey KW; Nicolau JC; Scirica BM; Storey RF; Vintila M; Ycas J; Wallentin L
    J Am Coll Cardiol; 2011 Feb; 57(6):672-84. PubMed ID: 21194870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ticagrelor, prasugrel, or clopidogrel in ST-segment elevation myocardial infarction: which one to choose?
    Guimarães PO; Tricoci P
    Expert Opin Pharmacother; 2015; 16(13):1983-95. PubMed ID: 26224244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial.
    Shimada YJ; Bansilal S; Wiviott SD; Becker RC; Harrington RA; Himmelmann A; Neely B; Husted S; James SK; Katus HA; Lopes RD; Steg PG; Storey RF; Wallentin L; Cannon CP;
    Am Heart J; 2016 Jul; 177():1-8. PubMed ID: 27297843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative effectiveness of clopidogrel in medically managed patients with unstable angina and non-ST-segment elevation myocardial infarction.
    Solomon MD; Go AS; Shilane D; Boothroyd DB; Leong TK; Kazi DS; Chang TI; Hlatky MA
    J Am Coll Cardiol; 2014 Jun; 63(21):2249-57. PubMed ID: 24703914
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiographic and electrocardiographic parameters of myocardial reperfusion in angioplasty of patients with ST elevation acute myocardial infarction loaded with ticagrelor or clopidogrel (MICAMI-TICLO trial).
    Winter JL; Lindefjeld DS; Veas N; Guarda E; Valdebenito M; Méndez M; Pérez O; Zuanic K; Mestas M; Martínez A
    Cardiovasc Revasc Med; 2014; 15(5):284-8. PubMed ID: 25178668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ticagrelor effects on myocardial infarction and the impact of event adjudication in the PLATO (Platelet Inhibition and Patient Outcomes) trial.
    Mahaffey KW; Held C; Wojdyla DM; James SK; Katus HA; Husted S; Steg PG; Cannon CP; Becker RC; Storey RF; Khurmi NS; Nicolau JC; Yu CM; Ardissino D; Budaj A; Morais J; Montgomery D; Himmelmann A; Harrington RA; Wallentin L;
    J Am Coll Cardiol; 2014 Apr; 63(15):1493-9. PubMed ID: 24561148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Health-related quality of life of ticagrelor versus clopidogrel in patients with acute coronary syndromes-results from the PLATO trial.
    Levin LÅ; Wallentin L; Bernfort L; Andersson D; Storey RF; Bergström G; Lamm CJ; Janzon M; Kaul P
    Value Health; 2013 Jun; 16(4):574-80. PubMed ID: 23796291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors contributing to the lower mortality with ticagrelor compared with clopidogrel in patients undergoing coronary artery bypass surgery.
    Varenhorst C; Alström U; Scirica BM; Hogue CW; Åsenblad N; Storey RF; Steg PG; Horrow J; Mahaffey KW; Becker RC; James S; Cannon CP; Brandrup-Wognsen G; Wallentin L; Held C
    J Am Coll Cardiol; 2012 Oct; 60(17):1623-30. PubMed ID: 23021325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: Data from the PLATO Trial.
    Patel MR; Becker RC; Wojdyla DM; Emanuelsson H; Hiatt WR; Horrow J; Husted S; Mahaffey KW; Steg PG; Storey RF; Wallentin L; James SK
    Eur J Prev Cardiol; 2015 Jun; 22(6):734-42. PubMed ID: 24830710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial.
    James S; Akerblom A; Cannon CP; Emanuelsson H; Husted S; Katus H; Skene A; Steg PG; Storey RF; Harrington R; Becker R; Wallentin L
    Am Heart J; 2009 Apr; 157(4):599-605. PubMed ID: 19332184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inactivations, deletions, non-adjudications, and downgrades of clinical endpoints on ticagrelor: serious concerns over the reliability of the PLATO trial.
    DiNicolantonio JJ; Tomek A
    Int J Cardiol; 2013 Oct; 168(4):4076-80. PubMed ID: 23911266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of Ticagrelor Versus Clopidogrel Treatment in Patients With ST-elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
    Tang X; Li R; Jing Q; Wang Q; Liu P; Zhang P; Liu Y
    J Cardiovasc Pharmacol; 2016 Aug; 68(2):115-20. PubMed ID: 27010809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Viewpoint: mismatch between the European and American guidelines on oral antiplatelet P2Y12 inhibitors after acute coronary syndromes.
    Serebruany VL; DiNicolantonio JJ
    Thromb Haemost; 2013 Jul; 110(1):5-10. PubMed ID: 23743577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative ST-depression in acute coronary syndromes: the PLATO electrocardiographic substudy.
    Armstrong PW; Westerhout CM; Fu Y; Harrington RA; Storey RF; Katus H; James S; Wallentin L
    Am J Med; 2013 Aug; 126(8):723-729.e1. PubMed ID: 23795897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.